Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
PMDA is regarded among the most stringent regulatory bodies globally
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
The biosimilar Ustekinumab has been developed and manufactured by the company
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Subscribe To Our Newsletter & Stay Updated
